Polarean’s Xenon MRI platform is opening a new window into the pulmonary microvasculature, long considered a “silent zone” in cardiopulmonary disease and reshaping how pharma sponsors evaluate therapeutic response...
The Medtech Incubator–Leap partnership seeks to streamline this process by delivering not just new devices, but supported, compliant, and operationally ready launches...
MFUSE is designed to support clinicians in managing external bleeding by forming a flexible hydrogel barrier when applied to the wound site...
Polarean is working in collaboration with VIDA Diagnostics (VIDA), providing centralised imaging operations, site orchestration, and advanced Xenon MRI biomarker analysis...
CART is positioning cuffless monitoring as a credible alternative to traditional 24-hour ambulatory devices...
Researchers develop an innovative dural patch that achieves rapid, watertight sealing of dural tears, boasting high biocompatibility...
Combines AI-powered technology with R1 experts to set a new standard for clearance and denial rates...
The investment - which is a substantial contribution from Verdane's €2 billion growth fund - is the single largest investment in Clue ...
The Breakthrough Device Designation is a distinction reserved for technologies that offer a more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases...
Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into pregnancy health...
